Locoregional control · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Toxicity / adverse effects (harms) of chemotherapy · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
1 finding from 1 review
Overall survival, induction platinum + 5-fluorouracil prior to radiotherapy vs radiotherapy alone · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… showed no clear difference in overall survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone (moderate certainty).
1 finding from 1 review
Disease-free survival · People receiving curative-intent treatment for oral cavity and oropharyngeal (squamous cell) cancer
Induction chemotherapy plus locoregional treatment (radiotherapy… led to lower disease-free survival, induction platinum + 5-fluorouracil prior to… compared with locoregional treatment (radiotherapy and/or surgery) alone; GRADE not reported.
1 finding from 1 review
Adverse effects of antibiotics · children, aged 2 to 59 months, with WHO‐defined non‐severe pneumonia and wheeze
Antibiotic therapy showed no clear difference in treatment harms (adverse events or side effects associated with… compared with placebo compared to placebo (low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether infrared light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether infrared light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether infrared light therapy changes overall discontinuation ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Incidence of SAD (SIGH‐SAD score ≥ 20) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of SAD (SIGH‐SAD score ≥ 20) ( compared with infrared light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with infrared light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes overall discontinuation ( compared with infrared light therapy (very low certainty).
1 finding from 1 review
Incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes incidence of severe SAD (SIGH‐SAD‐SR (≥ 40)) ( compared with no light therapy (very low certainty).
1 finding from 1 review
Overall discontinuation ( · All participants were known SAD patients who had been successfully treated with conventional light therapy in previous winters
It is very uncertain whether bright white light therapy changes overall discontinuation ( compared with no light therapy (very low certainty).
1 finding from 1 review
Adverse events Assessed by: number of participants with a global negative outcome (e.g. dropping out of therapy, recidivism or being transferred to another facility due to poor treatment response) overall Timing of assessment: over the 3 years · adults with antisocial personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher menstruation recovery or maintenance: compared with chemotherapy alone (low certainty).
2 findings from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy probably leads to lower premature ovarian failure compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy showed no clear difference in pregnancy compared with chemotherapy alone (low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
GnRH agonist plus chemotherapy may leads to higher ovulation compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effects: hot flush · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist plus chemotherapy changes adverse effects: hot flush compared with chemotherapy alone (very low certainty).
1 finding from 1 review